GI Disorders
GI Disorders Often Fueled by the Human Body’s ‘Second Brain’
The gut–brain–microbiome axis is a two-way street, with GI symptoms affected by stress and acting as a stressor, an expert noted during the AAPP 2025 annual meeting.
AUGUST 22, 2025
FMT May Boost Immunotherapy Effectiveness
Fecal microbiota transplantation may enhance the effectiveness of immunotherapies by reducing gut dysbiosis, according to a presentation at the 2025 ASCO Annual Meeting.
JULY 24, 2025
Tevimbra Approved for Some Patients With Unresectable or Metastatic ESCC
The FDA has approved Tevimbra, in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express programmed death ligand-1.
MARCH 4, 2025
FDA Approves Lumakras With Vectibix for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved Lumakras with Vectibix for adult patients with KRAS G12C–mutated metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
JANUARY 21, 2025
Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo
The FDA has approved Tevimbra, in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma cancers in some adults.
JANUARY 13, 2025
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
New Guideline for H. pylori Changes Primary Treatment Recommendation
The American College of Gastroenterology updated its 2017 guideline for treating Helicobacter pylori.
SEPTEMBER 24, 2024
Machine Learning Can Predict Best Responders to GLP-1s
Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond to GLP-1s.
SEPTEMBER 21, 2024
FDA Approves Guselkumab for UC
The FDA has approved Tremfya for patients with moderately to severely active ulcerative colitis.
SEPTEMBER 12, 2024
ACG Issues Updated Guidance on Alcohol-Associated Liver Disease
The American College of Gastroenterology recently published a guideline on alcohol-associated liver disease.
AUGUST 15, 2024
GLP-1RA Use Increases Gastric Food Retention Post-Endoscopy—But Fasting Mitigates This
Although patients appear more likely to retain stomach contents during endoscopic procedures, this risk may be mitigated by fasting protocol.
MAY 29, 2024
7 Steps to Manage Pruritus in Liver Disease
It’s not just patients with primary biliary cholangitis. Patients with liver disease of all different etiologies can develop pruritus.
MAY 29, 2024
